REG - Hikma Pharmaceutical - Result of AGM <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

12/05/2016 15:15

RNS Number : 1111Y
Hikma Pharmaceuticals Plc
12 May 2016
Hikma Pharmaceuticals PLC 
Voting Results of 2016 Annual General Meeting
LONDON, 12 May 2016 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at The Westbury, Bond Street, Mayfair, London W1S 2YF on 12 May 2016 commenced at 11:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 19 were passed as special resolutions. 
As previously announced, Mr. Breffni Byrne retired from the Board at the close of the AGM.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility. 
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2016). is set out below. The number of Ordinary Shares in issue on 12 May 2016 was 239,385,501.
Resolution
Votes For
%
Votes Against
%
Votes Withheld
1
To receive the 2015 report and accounts
201,043,426
99.83%
347,462
0.17%
197,375
2
To approve a final dividend of 21 cents per share
201,588,263
100.00%
0
0.00%
0
3
Appoint PricewaterhouseCoopers LLP as auditors
198,964,787
98.70%
2,623,476
1.30%
0
4
Authorise the Audit Committee to set the remuneration of the auditors
194,789,399
96.63%
6,798,864
3.37%
0
5
Appoint Jochen Gann
199,061,688
98.75%
2,526,551
1.25%
0
6
Appoint John Castellani
200,675,819
99.55%
912,421
0.45%
0
7
Reappointment of Said Darwazah
196,614,743
97.69%
4,641,117
2.31%
332,378
8
Reappointment of Mazen Darwazah
197,410,765
97.93%
4,177,474
2.07%
0
9
Reappointment of Robert Pickering
199,988,353
99.21%
1,599,886
0.79%
0
10
Reappointment of Ali Al Husry
199,090,927
98.76%
2,497,312
1.24%
0
11
Reappointment of Michael Ashton
196,521,848
98.45%
3,095,916
1.55%
1,970,475
12
Reappointment of Ronald Goode
198,210,008
99.05%
1,901,133
0.95%
1,477,098
13
Reappointment of Patrick Butler
200,562,012
99.49%
1,026,227
0.51%
0
14
Reappointment of Dr Pamela Kirby
199,880,568
99.15%
1,707,671
0.85%
0
15
Approve the 2015 remuneration implementation
173,423,087
88.97%
21,510,812
11.03%
6,654,338
16
Authorise the directors to allot shares
176,261,935
87.65%
24,841,433
12.35%
484,894
17
Disapply pre-emption rights
179,904,929
90.65%
18,558,726
9.35%
3,124,607
18
Authorise the company to buy back shares
200,673,199
99.55%
915,063
0.45%
0
19
Authorise the company to call general meetings on 14 days' notice
185,097,715
91.88%
16,365,074
8.12%
125,473
Declaration of final dividend
The dividend of 21 cents per share will be paid on 19 May 2016 to shareholders on the register on 8 April 2016. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.4510 to 1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at 1JD to $1.4104.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
Susan Ringdal
VP for Investor Relations and Strategy
+44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGSFFFLEFMSEFI